Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months

(2010) Lourdes Ibáñez et al.   GYNECOLOGICAL ENDOCRINOLOGY

Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome

(2010) Irene Lambrinoudaki   MATURITAS

α-Tocopherol Is Ineffective in Preventing the Decomposition of Preformed Lipid Peroxides and May Promote the Accumulation of Toxic Aldehydes: A Potential Explanation for the Failure of Antioxidants to Affect Human Atherosclerosis

(2009) Achuthan Raghavamenon et al.   ANTIOXIDANTS & REDOX SIGNALING

Metabonomic Study of Ochratoxin A Toxicity in Rats after Repeated Administration: Phenotypic Anchoring Enhances the Ability for Biomarker Discovery

(2009) Maximilian Sieber et al.   CHEMICAL RESEARCH IN TOXICOLOGY

The role of pioglitazone in modifying the atherogenic lipoprotein profile

(2009) M. Hanefeld   DIABETES OBESITY & METABOLISM

Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months

(2008) Lourdes Ibáñez et al.   CLINICAL ENDOCRINOLOGY